University of California San Diego School of Medicine

• Ruxolitinib cream demonstrates positive long-term safety profile in atopic dermatitis patients, with lower rates of cutaneous infections compared to untreated populations according to extended clinical trial data. • The JAK inhibitor topical treatment outperforms mid-potency corticosteroids while being suitable for delicate skin areas including the face and body folds, potentially preventing progression to systemic therapy. • Experts emphasize shared decision-making as crucial in atopic dermatitis management, with treatment plans tailored to patient history, disease severity, and consideration of the skin microbiome's role in disease pathogenesis.

A clinical trial revealed that cetuximab is more effective than durvalumab in treating head and neck cancers for patients who cannot tolerate cisplatin.